Expert Interview
A Second Look: Discussing the primary results from the KOMET Phase 3 trial (NCT04924608) presented at ASCO, evaluating Koselugo (selumetinib) in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma.
Ticker(s): AZN, SWTX.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
